

Embargoed until 7.00 a.m. on November 4, 2015

Key Financial Data:

January 1 to September 30, 2015 / Q3 2015

November 4, 2015

Tim Lange

Head of Investor Relations

Phone +49 201 177-3150

tim.lange@evonik.com

Evonik delivers third strong quarter in a row

- Strong business performance continued in the second half of the year
- Sales grew 4 percent to €3.4 billion
- Adjusted EBITDA up considerably year-on-year at €653 million (+31 percent), and therefore in line with the previous quarters' high level
- Year-on-year earnings growth in all three chemical segments
- Adjusted EBITDA margin of 19.4 percent stands out in the chemicals sector
- Outlook for 2015 confirmed

Essen. "Evonik remains successful," said Klaus Engel, Chairman of the Executive Board of Evonik Industries AG today, when the Group published its key financial figures for the third quarter of 2015 and the interim report for the period from January to September 2015. He explained the reasons for this: "Our business is continuing to develop at a high level in the second half of the year. It is also pleasing to report that all three chemical segments were able to increase their earnings year-on-year in the third quarter. Building on that and on our belief in our performance, we are looking ahead with confidence."

At Group level, both sales and adjusted EBITDA continued the strong performance seen in the first two quarters of the year. Global demand for Evonik's products was again good. However, volumes were slightly lower than in the third quarter of 2014 as a consequence of routine plant maintenance. There was a considerable increase in selling prices in the Nutrition & Care segment, whereas prices in the Performance Materials segment declined, mainly because of the drop in the oil price. Overall, selling prices were higher than in the previous quarter.

Evonik Industries AG

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Telefax +49 201 177-3475

www.evonik.com

Supervisory Board

Dr. Werner Müller, Chairman

Executive Board

Dr. Klaus Engel, Chairman

Dr. Ralph Sven Kaufmann

Christian Kullmann

Thomas Wessel

Ute Wolf

Registered office Essen

Registered court

Essen local court

Commercial registry B 19474

VAT ID no. DE 811160003

Key data for the Evonik Group Q3 and first nine months of 2015

Driven by higher prices and positive currency effects, sales increased by 4 percent to €3,365 million in the third quarter, and by 6 percent to €10,309 million in the first nine months, supported by higher volumes. The Group's adjusted EBITDA climbed 31 percent to €653 million in the third quarter and therefore remained at the high level reported for the previous quarters. In the first nine months, adjusted EBITDA rose 37 percent to €1,964 million. This was attributable to the ongoing good volume trend, partly as a result of new capacities, and to higher selling prices. Further positive factors were slightly lower raw material costs and currency effects. The adjusted EBITDA margin of 19.4 percent in the third quarter stood out in the chemicals sector. Between January and September the adjusted EBITDA margin rose to 19.1 percent, up from 14.8 percent in the prior-year period. Adjusted net income increased 36 percent to €296 million in the third quarter and 56 percent to €923 million in the first nine months. The strong business performance so far this year has had a favorable impact on the cash flow from operating activities. At €1,329 million at the end of the first nine months it was already well above the cash flow of €1,066 million reported for 2014 as a whole.

Outlook for the year confirmed

In view of the continued strong business performance, Evonik is confirming its expectations for the full year. Given the strong development of the operating business, in mid-year the company raised its guidance to sales of around €13.5 billion (2014: €12.9 billion) and adjusted EBITDA of around €2.4 billion (2014: €1.9 billion).

Segment performance

For the first time in 2015, all three chemical segments reported a year-over-year improvement in earnings in the third quarter.

In the **Nutrition & Care** segment sales grew 22 percent to €1,240 million in the third quarter (Q3 2014: €1,016 million). While volumes rose slightly, the main drivers were far higher selling prices and positive currency effects. Thanks to higher prices and lower raw material costs, adjusted EBITDA increased 85 percent to €382 million. The adjusted EBITDA margin rose significantly from 20.3 percent in the prior-year period to 30.8 percent.

Sales in the **Resource Efficiency** segment increased 2 percent to €1,044 million in the third quarter (Q3 2014: €1,027 million) as a result of slightly higher selling prices and positive currency effects. The slight reduction in volumes was attributable to routine maintenance work at some production plants. Adjusted EBITDA increased slightly to €216 million. The adjusted EBITDA margin was around the prior-year level at 20.7 percent.

In the **Performance Materials** segment sales declined 11 percent to €858 million in the third quarter (Q3 2014: €966 million). Alongside plant maintenance in the two most important businesses, this was because selling prices were impacted by the persistently low oil price. On the earnings side, however, this price effect was more than offset by a temporary margin advantage as a result of the reduction in the cost of oil-based feedstocks. Adjusted EBITDA therefore improved by 4 percent to €94 million (Q3 2014: €90 million). The adjusted EBITDA margin was 11 percent, up from 9.3 percent in the third quarter of 2014.

Evonik Group: Excerpt from the income statement

(in € million)	Q3 2015	Q3 2014	Change in %	9M 2015	9M 2014	Change in %
Sales	3,365	3,243	4	10,309	9,691	6
Adjusted EBITDA	653	500	31	1,964	1,436	37
Adjusted EBIT	473	349	36	1,444	988	46
Adjustments	-91	-54		-6	-144	
Financial result	-86	-63		-200	-211	
Income before income taxes, continuing operations	296	232	28	1,238	633	96
Income taxes	-105	-64		-354	-196	
Income after taxes, continuing operations	191	168	14	884	437	102
Income after taxes, discontinued operations	-	-54		-15	-11	
Income after taxes	191	114	68	869	426	104
thereof attributable to non-controlling interests	3	3		7	10	
Net income	188	111	69	862	416	107
Adjusted net income	296	217	36	923	593	56

Prior-year figures restated

Segment performance

	Sales Q3			Adjusted EBITDA Q3		
	2015 € million	2014 € million	Change in %	2015 € million	2014 € million	Change in %
Nutrition & Care	1,240	1,016	22	382	206	85
Resource Efficiency	1,044	1,027	2	216	214	1
Performance Materials	858	966	-11	94	90	4
Services	207	217	-5	46	47	-2
Other operations	16	17		-85	-57	
Group	3,365	3,243	4	653	500	31
	Sales 9M			Adjusted EBITDA 9M		
	2015 € million	2014 € million	Change in %	2015 € million	2014 € million	Change in %
Nutrition & Care	3,716	2,961	25	1,116	578	93
Resource Efficiency	3,278	3,069	7	714	661	8
Performance Materials	2,646	2,944	-10	247	253	-2
Services	626	671	-7	123	135	-9
Other operations	43	46		-236	-191	
Group	10,309	9,691	6	1,964	1,436	37

Prior-year figures restated

Employees by segment

	Sept. 30, 2015	Dec. 31, 2014
Nutrition & Care	7,062	6,943
Resource Efficiency	8,549	7,835
Performance Materials	4,387	4,353
Services	12,747	13,173
Other operations	905	937
Continuing operations	33,650	33,241
Discontinued operations	-	171
Group	33,650	33,412

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.